» Articles » PMID: 6454754

Characterization of a Soluble Suppressor of Human B Cell Immunoglobulin Biosynthesis Produced by a Continuous Human Suppressor T Cell Line

Overview
Journal J Exp Med
Date 1981 Jul 1
PMID 6454754
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A human suppressor T cell maintained in long-term culture with conditioned medium containing interleukin 2 elaborates a suppressor factor(s) that specifically inhibits human polyclonal B cell immunoglobulin biosynthesis. This soluble immune suppressor supernate of immunoglobulin production (CTC-SISS-B) shares a number of features with the previously described suppressive mediator elaborated by concanavalin A-activated human peripheral T cells (SISS-B) including: (a) the inhibition by a noncytotoxic mechanism, (b) the suppression of immunoglobulin biosynthesis either through direct action on the B cell or indirect action via the monocyte, (c) the loss of inhibition in the presence of the monosaccharide L-rhamnose, (d) the elaboration by cells irradiated with 500 ro 2,000 rad, and (e) molecular weights of 60,000--90,000. Furthermore, the suppression by this mediator appears to be specific for B cell immunoglobulin production in that CTC-SISS B has no effect on T cell proliferation to mitogens, antigens, an allogeneic cells or on T cell-mediated cytotoxicity. These data indicate that one possible mechanism of suppressor T cell inhibition of human immunoglobulin production is via the generation of a lectinlike suppressor lymphokine that interacts with defined saccharide determinants on the cell surface of either the B cell or monocyte.

Citing Articles

Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the....

Waldmann T, Greene W, SARIN P, Saxinger C, Blayney D, Blattner W J Clin Invest. 1984; 73(6):1711-8.

PMID: 6327770 PMC: 437083. DOI: 10.1172/JCI111379.


Reversal of infectious mononucleosis-associated suppressor T cell activity by D-mannose.

Tosato G, Pike S, Blaese R J Exp Med. 1983; 158(4):1048-60.

PMID: 6225821 PMC: 2187377. DOI: 10.1084/jem.158.4.1048.


Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels.

Pilarski L, Ruether B, Mant M J Clin Invest. 1985; 75(6):2024-9.

PMID: 2989339 PMC: 425563. DOI: 10.1172/JCI111921.


Use of anti-idiotypic antibodies to identify a receptor for the T-cell I-J determinant.

Zupko K, Waltenbaugh C, Diamond B Proc Natl Acad Sci U S A. 1985; 82(21):7399-403.

PMID: 2932739 PMC: 391352. DOI: 10.1073/pnas.82.21.7399.


Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma.

Ebihara T, Koyama S, Fukao K, Osuga T Cancer Immunol Immunother. 1989; 28(3):218-24.

PMID: 2522349 PMC: 11038667. DOI: 10.1007/BF00204992.

References
1.
Pick E, Turk J . The biological activities of soluble lymphocyte products. Clin Exp Immunol. 1972; 10(1):1-23. PMC: 1713087. View

2.
Waldmann T, POLMAR S, Balestra S, Jost M, Bruce R, TERRY W . Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE concentration of patients with acquired hypogammaglobulinemia, thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal lymphangiectasia and Wiskott-Aldrich syndrome. J Immunol. 1972; 109(2):304-10. View

3.
David J, DAVID R . Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators. Prog Allergy. 1972; 16:300-449. View

4.
Glade P, Papageorgiou P . Human lymphoid cell lines: models for immunological analysis. In Vitro. 1973; 9(3):202-15. DOI: 10.1007/BF02618438. View

5.
Papageorgiou P, Sorokin C, Glade P . Similarity of migration inhibitory factor(s) produced by human lymphoid cell line and phytohemagglutinin and tuberculin-stimulated human peripheral lymphocytes. J Immunol. 1974; 112(2):675-82. View